No Data
No Data
beijing sl pharmaceutical (002038.SZ): Executive Liang Shujie completes the shareholding of 0.5 million shares
On October 16, the Bejing SL Pharmaceutical (002038.SZ) announced that the company recently received a notice from senior executive Ms. Liang Shujie, informing the completion of the shareholding reduction plan, with a total reduction of 0.5 million shares, accounting for 0.0487% of the company's total share capital.
Director and board secretary Liang Shujie of Beijing SL Pharmaceutical (002038.SZ) reduced 0.5 million shares.
beijing sl pharmaceutical (002038.SZ) announcement, Ms. Liang Shujie, director and secretary of the board of directors, resigned from the company on July 16, 2024...
Beijing SL Pharmaceutical (002038.SZ): obtained the registration certificate for the pharmaceutical injection of Leuprorelin.
On October 15th, Beijing SL Pharmaceutical (002038.SZ) announced that the company recently received the approval and issuance of the registration certificate of the pharmaceutical Eptifibatide Injection (trade name: Yiven) (10ml:20mg) by the National Medical Products Administration. Eptifibatide is a specific platelet glycoprotein IIb/IIIa receptor antagonist that reverses the ischemic state caused by thrombus formation by selectively and reversibly inhibiting the final common pathway of platelet aggregation. It is mainly used clinically for post-intervention anti-thrombotic treatment in patients with acute coronary syndrome, and can also be used in non-atherosclerotic vascular diseases.
Beijing Sl Pharmaceutical: Half-year report for the year 2024.
Beijing Sl Pharmaceutical: Summary of Half-Year Report in 2024.
Beijing Sl Pharmaceutical: Beijing SL Pharmaceutical Co., Ltd. announces its performance forecast for the first half of 2024.
No Data
No Data